Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations

The T790M secondary mutation of the epidermal growth factor receptor (EGFR) gene accounts for 50% to 60% of cases of resistance to the first-generation EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. The prevalence of T790M in EGFR mutation–positive patients who acquire resistance to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Tanaka, Kentaro, Nosaki, Kaname, Otsubo, Kohei, Azuma, Koichi, Sakata, Shinya, Ouchi, Hiroshi, Morinaga, Ryotaro, Wataya, Hiroshi, Fujii, Akiko, Nakagaki, Noriaki, Tsuruta, Nobuko, Takeshita, Masafumi, Iwama, Eiji, Harada, Taishi, Nakanishi, Yoichi, Okamoto, Isamu
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5620242/
https://ncbi.nlm.nih.gov/pubmed/28978102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19243
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados